Feasibility study [9] | AIR study [6] | RISA study [5] | AIR2 study [7] | |
Age years | ≥18 | 18–65 | 18–65 | 18–65 |
ICS dose# μg | ≤1500 or 200–1800¶ | ≥200 | >1500 | >1000 |
LABA dose μg | 0–100 | ≥100 | ≥100 | ≥100 |
OCS dose mg·day−1 | 0 | 0 | ≤30 | ≤10 |
Pre-BD FEV1 % predicted | 60–85 | 60–85 | ≥50 | ≥60 |
AIR: Asthma Intervention Research; RISA: Research in Severe Asthma; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; OCS: oral corticosteroids; BD: bronchodilator; FEV1: forced expiratory volume in 1 s. #: beclomethasone dipropionate equivalent; ¶: inclusion criteria different at the two participating sites (Narinder Shargill, Boston Scientific, San Jose, CA, USA; personal communication).